Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Finrozole (MPV 2213ad) 是一种新型选择性芳香化酶抑制剂,对于乳房发育是部分可逆的。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 910 | 现货 | ||
5 mg | ¥ 2,230 | 现货 | ||
10 mg | ¥ 3,350 | 现货 | ||
25 mg | ¥ 5,460 | 现货 | ||
50 mg | ¥ 7,670 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
500 mg | ¥ 19,800 | 现货 |
产品描述 | Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development. |
体内活性 | To investigate the pharmacokinetics of finrozole (MPV-2213ad), a novel competitive aromatase enzyme inhibitor, in healthy male volunteers. METHODS: The study was an open, partly randomized cross-over study including 23 volunteers receiving single doses of 3, 9 mg, or 30 mg of finrozole as tablets or solution with 14 days between the administrations. The highest dose was given as tablets only. Serum concentrations of finrozole were determined using high performance liquid chromatography combined with mass spectrometry. RESULTS: The mean time to peak serum concentration ranged from 2.5 to 3.1, and 0.6-0.7 h after tablets and solution, respectively. The Cmax values increased as the dose increased. The calculated apparent mean elimination half-life (t(1/2,z)) was approximately 3 h after the solution, and approximately 8 h after the tablet. The AUC(0, infinity) after finrozole tablets increased proportionally from 3 mg to 9 mg and from 3 to 30 mg. The calculated relative mean bioavailabilities (AUC(0, infinity)-ratio) for the 3 mg and 9 mg doses of finrozole as tablets were 89% and 78%, respectively. CONCLUSIONS: The absorption of finrozole from the tablet formulation was relatively rapid, and the apparent elimination half-life was longer after the tablet than after the solution, probably reflecting the overlap of the absorption with the elimination phase.[1] |
别名 | MPV 2213ad, MPV-2213ad, MPV 2213, MPV-2213, MPV2213ad |
分子量 | 322.34 |
分子式 | C18H15FN4O |
CAS No. | 160146-17-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (155.12 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1023 mL | 15.5116 mL | 31.0231 mL | 77.5579 mL |
5 mM | 0.6205 mL | 3.1023 mL | 6.2046 mL | 15.5116 mL | |
10 mM | 0.3102 mL | 1.5512 mL | 3.1023 mL | 7.7558 mL | |
20 mM | 0.1551 mL | 0.7756 mL | 1.5512 mL | 3.8779 mL | |
50 mM | 0.062 mL | 0.3102 mL | 0.6205 mL | 1.5512 mL | |
100 mM | 0.031 mL | 0.1551 mL | 0.3102 mL | 0.7756 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Finrozole 160146-17-8 Endocrinology/Hormones Aromatase MPV 2213ad MPV2213 MPV-2213ad MPV 2213 MPV-2213 MPV2213ad Inhibitor inhibitor inhibit